Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00463762|
Recruitment Status : Withdrawn
First Posted : April 20, 2007
Last Update Posted : April 22, 2011
|Condition or disease||Intervention/treatment||Phase|
|Abscess, Intra-Abdominal Cholecystitis Wound Infections Peritonitis Appendicitis||Drug: CP-75385-02 Cefoperazone/sulbactam||Phase 4|
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections In Slovakia. An Open, Prospective, Non-Comparative Study.|
|Study Start Date :||May 2007|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00463762
|Study Director:||Pfizer CT.gov Call Center||Pfizer|